PDF(Pubmed)
Abstract：
BACKGROUND: Current therapy for patients suffering from inflammatory bowel diseases (IBD) is focused on inflammatory mechanisms exclusively and not the dysbiotic microbiota, despite growing evidence implicating a role for intestinal microbes in disease.
METHODS: Ongoing research into the intestinal microbiota of IBD patients, using new technologies and/or deeper application of existing ones, has identified a number of microorganisms whose properties and behaviors warrant consideration as causative factors in disease. Such studies have implicated both bacteria and fungi in the pathogenesis of disease. Some of these organisms manifest mechanisms that should be amenable to therapeutic intervention via either conventional or novel drug discovery platforms. Of particular note is a deeper characterization of microbial derived proteases and their destructive potential.
CONCLUSIONS: Given the steady progress on the mechanistic role of the microbiota in inflammatory diseases, it is reasonable to anticipate a future in which therapeutics targeting microbial derived pathogenic factors play an important role in improving the lives of IBD patients.
METHODS: Ongoing research into the intestinal microbiota of IBD patients, using new technologies and/or deeper application of existing ones, has identified a number of microorganisms whose properties and behaviors warrant consideration as causative factors in disease. Such studies have implicated both bacteria and fungi in the pathogenesis of disease. Some of these organisms manifest mechanisms that should be amenable to therapeutic intervention via either conventional or novel drug discovery platforms. Of particular note is a deeper characterization of microbial derived proteases and their destructive potential.
CONCLUSIONS: Given the steady progress on the mechanistic role of the microbiota in inflammatory diseases, it is reasonable to anticipate a future in which therapeutics targeting microbial derived pathogenic factors play an important role in improving the lives of IBD patients.
摘要：
背景：目前针对炎症性肠病（IBD）患者的治疗仅集中在炎症机制上，而不是微生态微生物群。尽管越来越多的证据暗示肠道微生物在疾病中的作用。
方法：正在进行的IBD患者肠道菌群研究，使用新技术和/或对现有技术的更深入应用，已经确定了许多微生物，其特性和行为值得考虑为疾病的致病因素。这样的研究已经将细菌和真菌都牵涉到疾病的发病机理中。这些生物体中的一些表现出的机制应该适合于通过常规或新型药物发现平台的治疗干预。特别值得注意的是对微生物来源的蛋白酶及其破坏潜力的更深入表征。
结论：鉴于微生物群在炎症性疾病中的机制作用的稳步进展，有理由预测未来,针对微生物来源的致病因子的治疗在改善IBD患者的生活中发挥重要作用。
方法：正在进行的IBD患者肠道菌群研究，使用新技术和/或对现有技术的更深入应用，已经确定了许多微生物，其特性和行为值得考虑为疾病的致病因素。这样的研究已经将细菌和真菌都牵涉到疾病的发病机理中。这些生物体中的一些表现出的机制应该适合于通过常规或新型药物发现平台的治疗干预。特别值得注意的是对微生物来源的蛋白酶及其破坏潜力的更深入表征。
结论：鉴于微生物群在炎症性疾病中的机制作用的稳步进展，有理由预测未来,针对微生物来源的致病因子的治疗在改善IBD患者的生活中发挥重要作用。
